Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Efaproxiral regulatory update

ALTH received an FDA approvable letter for its NDA for RSR13 efaproxiral plus whole brain radiation therapy (WBRT) to treat brain metastases originating from breast cancer. ALTH said FDA

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE